Premium
Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity
Author(s) -
Laursen A. Lund,
Gerlach J.
Publication year - 1986
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1986.tb02659.x
Subject(s) - benzamide , antipsychotic , pharmacology , medicine , chemistry , psychiatry , medicinal chemistry , schizophrenia (object oriented programming)
Ten of 14 schizophrenic patients completed a 6‐week pilot study with a new substituted benzamide, remoxipride. The final median dose was 600 mg/day (range 300–1200) corresponding to a plasma concentration of 5.16 μmol/l (1.55–11.50). Remoxipride reduced the psychotic symptomatology, especially hallucinations and delusions. The total Brief Psychiatric Rating Scale score decreased from 33.5 to 13.0 ( P < 0.01). Few side effects occurred; four patients had weak extrapyramidal symptoms, and four were slightly sedated. No cardiovascular side effects occurred. Prolactin increased, but apparently less than during sulpiride treatment.